@article{0263d18be79240c1bf50d1edf9ac0d10,
title = "Spotlight on the DRCR Retina Network's Photobiomodulation for Diabetic Macular Edema Trial",
author = "Sun, {Jennifer K.} and Glassman, {Adam R.} and Jampol, {Lee M.}",
note = "Funding Information: receiving grants from Jaeb Center during the conduct of the study and grants from Boehringer Ingelheim, Janssen, JDRF, Optovue, and Physical Sciences Inc; nonfinancial support from Adaptive Sensory Technologies, Boston Micromachines, Genentech/Roche, KalVista Pharmaceuticals, Merck, Novartis, and Novo Nordisk; and personal fees from the American Diabetes Association and JAMA Ophthalmology outside the submitted work. Dr Glassman reported receiving grants from the National Institutes of Health and nonfinancial support from PhotoOpTx during the conduct of the study and grants from Regeneron outside the submitted work. Dr Jampol reported receiving grants from Jaeb Center and the National Eye Institute during the conduct of the study. Funding Information: The downtime resulting from COVID-19 disruptions/closures turned out to have been a boon for many panelists, providing opportunities to learn new skills, analyze data, forge new research directions, write publications, and apply for grants. Panelists spoke about being awarded their first NIH K01 (training grant) or first K23 (clinician-scientist grant), private foundation funding, COVID-19–related NIH grant, or industry support. Some used the downtime to apply for their first R01 grant, to complete their dissertation,toreceivetheirPhD,ortosecuretheirfirstpostdoctoralposition. One panelist said that they used the time to organize a team to apply for an NIH telemedicine grant to deliver eye care through community-based health clinics.",
year = "2022",
month = apr,
doi = "10.1001/jamaophthalmol.2021.6331",
language = "English (US)",
volume = "140",
pages = "305--306",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "4",
}
